Feasibility for development of a liposome/LNP displaying an HIV ENV trimer protein and &*@~containing/incorporating an mrna.
Active Awarded Last action
- Contract number
- 75N93024F00001
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,919,133
Award facts
- Opportunity
-
- 75N93024R00035 Solicitation number
- Contract value 51% obligated
- $3,782,538.00 Current and potential, with all options
- Completion date 54% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $1,919,133 | |
| Original award | $1,863,405 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $3.78M to Advanced Bioscience Laboratories, Inc. (ABL) on August 31, 2024, for feasibility studies on developing a liposome/lipid nanoparticle (LNP) displaying an HIV envelope trimer protein and incorporating messenger RNA (mRNA). The contract, which extends through August 27, 2028, operates under a cost-plus-fixed-fee pricing structure with no set-aside designation. Work will be performed at ABL's facility in Potomac, Maryland. This delivery order falls under NIAID's larger Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents master indefinite delivery vehicle, which supports the agency's comprehensive efforts to advance vaccine candidates across multiple infectious disease priorities.
ABL is a contract research and manufacturing organization with extensive experience in biopharmaceutical development, particularly in vaccine and therapeutic manufacturing for government and commercial clients. The company has established itself as a key partner to NIAID and other National Institutes of Health components, holding multiple large indefinite delivery vehicles totaling hundreds of millions of dollars in potential value for preclinical development, cGMP manufacturing, and nonclinical testing services. Under this specific award, ABL will leverage its expertise in biologics manufacturing and translational development to assess the technical and manufacturing feasibility of an mRNA-based HIV vaccine platform, supporting NIAID's broader vaccine development mission for HIV prevention and treatment.
Quick answers
Who was awarded contract 75N93024F00001?
75N93024F00001 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 31, 2024.
How much is contract 75N93024F00001 worth?
The government has obligated $1,919,133 on 75N93024F00001. Its current value, with exercised options, is $3,782,538.
Is contract 75N93024F00001 an order under another contract?
Yes. 75N93024F00001 is a delivery order under 75N93022D00004, an indefinite delivery contract, on Preclinical And Translational Vaccine Development For HIV And Other Candidate Agents.
Was contract 75N93024F00001 competed?
The extent of competition for 75N93024F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award